Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

Inhibition of PARP is a promising therapeutic strategy for homologous recombination-deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2013-01, Vol.3 (1), p.68-81
Hauptverfasser:	Jaspers, Janneke E, Kersbergen, Ariena, Boon, Ute, Sol, Wendy, van Deemter, Liesbeth, Zander, Serge A, Drost, Rinske, Wientjens, Ellen, Ji, Jiuping, Aly, Amal, Doroshow, James H, Cranston, Aaron, Martin, Niall M B, Lau, Alan, O'Connor, Mark J, Ganesan, Shridar, Borst, Piet, Jonkers, Jos, Rottenberg, Sven
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use ATP Binding Cassette Transporter, Subfamily B, Member 1 - deficiency BRCA1 Protein - genetics Cell Line, Tumor Chromosomal Proteins, Non-Histone - genetics DNA Damage DNA-Binding Proteins - genetics Drug Resistance, Neoplasm Enzyme Inhibitors - therapeutic use Female Mammary Neoplasms, Animal - drug therapy Mice Mutation Phthalazines - therapeutic use Piperazines - therapeutic use Piperidines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors Tumor Suppressor p53-Binding Protein 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!